This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PDL BioPharma, Inc. (PDLI) Jumps: Stock Rises 8.2%
by Zacks Equity Research
PDL BioPharma, Inc. (PDLI) was a big mover last session, as the company saw its shares more than 8% on the day amid huge volumes.
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
by Zacks Equity Research
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
by Zacks Equity Research
Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q3. However, shares were down in after-hours trading.
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings top estimates in Q3. Revenues also grow year over owing to rise in royalty rights.
Amgen Label Expansion Application for Prolia Accepted by FDA
by Zacks Equity Research
Amgen (AMGN) announced that the FDA has accepted its regulatory application in the U.S. seeking label expansion for Prolia for treating patients with glucocorticoid-induced osteoporosis (GIOP).
Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
ProQR's Genetic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
ProQR Therapeutics (PRQR) announced that its investigational dystrophic epidermolysis bullosa candidate, QR-313, was granted orphan drug designation by the FDA.
Should Value Investors Consider PDL BioPharma, Inc. (PDLI) Stock?
by Zacks Equity Research
PDL BioPharma is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Pluristem's Ischemia Candidate Gets Fast Track Designation
by Zacks Equity Research
Pluristem Therapeutics' (PSTI) phase III study of PLX-PAD cells in patients with critical limb ischemia granted Fast Track designation by the FDA.
3 Pharma/Biotech Sector Bargains for a Healthy Portfolio
by Zacks Equity Research
The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.
Why PDL BioPharma (PDLI) Could Be Positioned for a Surge
by Zacks Equity Research
PDL BioPharma, Inc. (PDLI) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
by Zacks Equity Research
Zacks.com featured highlights Summer Infant, Intra-Cellular Therapies, PDL BioPharma, Cogentix Medical and Intrepid Potash
5 Bargain Breakout Stocks Offering Stunning Returns
by Swarup Gupta
The key to this kind of stock selection is to identify players that are trading within a narrow band.
Top Ranked Momentum Stocks to Buy for August 24th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 24th:
Top Ranked Momentum Stocks to Buy for August 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 23rd:
3 Reasons Why PDL BioPharma (PDLI) is a Great Momentum Stock
by Zacks Equity Research
PDL BioPharma (PDLI) stock is looking quite impressive now for momentum-oriented investors.
Top Ranked Momentum Stocks to Buy for August 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 16th:
PDL BioPharma (PDLI) Q2 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings surpass expectations. Revenues also significantly increase year over year, thanks to a rise in fair value of the Depomed royalty asset.
PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
PDL BioPharma (PDLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can PDL BioPharma Be a Top Choice for Value Investors?
by Zacks Equity Research
Value Investors might consider PDL BioPharma (PDLI) as a great pick on the back of its key value statistics.